Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Sirona Biochem Corp > Change of operational policy
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by Shockeron Dec 09, 2022 1:13pm
134 Views
Post# 35162119

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Change of operational policy

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Change of operational policyAnyone who sends near 200 post is a pumper/works for Sirona and last choice is PRC. 

Accountability runs to all the people groups and most of Sirona. I have no clue how much the CEO, CFO, PRC and mangement or any new staff or advisor, They represent the shareprice without the ability to bring confidence Or is the confidence come from Biorun dont sell

I am not sure what is worse by the first quarter in 2023 a contract with numbers. clear picture of how long China will bring any revenues or the path taken or does the LOI will be a long term nothing to report

My quess is 6 cents abd back to numbers from years ago. ikind of have a small hope that these deals have passed significantly, but does not mean they will use the product. Do we have a number on haow much R&F has paid us since that contract has been signed ????


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities